Clinical Trial Update: Study of Trilaciclib and Lurbinectidin [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating the combination of trilaciclib and lurbinectedin for lung cancer, including small cell lung cancer, is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lung Cancer
• Small Cell Lung Cancer

Drugs mentioned

• Lurbinectedin (lurbinectedin)
• trilaciclib (trilaciclib)

Snippet

Sponsor: UNC Lineberger Comprehensive Cancer Center | Conditions: Lung Cancer, Small-cell Lung Cancer | Phase 2 | Status: RECRUITING